Psychopharmacology

, Volume 198, Issue 3, pp 351–362

The effects of chronic versus acute desipramine on nicotine withdrawal and nicotine self-administration in the rat

  • Neil E. Paterson
  • Svetlana Semenova
  • Athina Markou
Original Investigation
  • 80 Downloads

Abstract

Rationale

Nicotine withdrawal is characterized by depression-like symptomatology that may be mediated by dysregulations in norepinephrine transmission. These aversive aspects of nicotine withdrawal and the rewarding effects of nicotine play major roles in maintaining nicotine dependence.

Objectives

The aim of this work was to evaluate the effects of desipramine (DMI), a preferential norepinephrine reuptake inhibitor and antidepressant, on preclinical models of nicotine dependence in rats.

Materials and methods

A rate-independent current-intensity discrete-trial threshold intracranial self-stimulation procedure was used to assess brain reward function during nicotine withdrawal induced by cessation of nicotine infusion via subcutaneous osmotic mini pumps (3.16 mg/kg/day, base). Nicotine withdrawal was also measured by somatic signs of withdrawal. DMI was administered acutely (2 or 5 mg/kg, salt) during nicotine/saline withdrawal. In other naïve rats, chronic DMI treatment via mini pump (15 mg/kg/day, salt) began after 7 days of nicotine/saline exposure and continued during administration of nicotine/saline for 14 days and during nicotine/saline withdrawal. Additional rats acquired intravenous nicotine- or food-maintained responding, were prepared with DMI/vehicle-containing mini pumps, and self-administered nicotine or food during 12 days of DMI/vehicle exposure.

Results

Acute DMI administration had no effect on threshold elevations observed in nicotine-withdrawing rats. Chronic DMI administration prevented the reward threshold elevations and the increased somatic signs of nicotine withdrawal. Although chronic DMI significantly decreased nicotine self-administration, it also decreased food-maintained responding.

Conclusions

The results suggest that norepinephrine reuptake inhibitors may be effective anti-smoking treatments that reduce the anhedonic depression-like and somatic components of nicotine withdrawal and may alter the rewarding effects of nicotine and food.

Keywords

Nicotine Withdrawal Self-administration Brain stimulation reward Somatic signs Desipramine Norepinephrine Rats 

References

  1. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Press, Washington, DCGoogle Scholar
  2. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG, Frazer A (1999) Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 19:10494–10501PubMedGoogle Scholar
  3. Benmansour S, Altamarino AV, Jones DJ, Sanchez TA, Gould GG, Pardon MC et al (2004) Regulation of the norepinephrine transporter by chronic administration of antidepressants. Biol Psychiatry 55:313–316PubMedCrossRefGoogle Scholar
  4. Blokhina EA, Kashkin VA, Zvartau EE, Danysz W, Bespalov AY (2005) Effects of nicotinic and NMDA receptor channel blockers on intravenous cocaine and nicotine self-administration in mice. Eur Neuropsychopharmacol 15:219–225PubMedCrossRefGoogle Scholar
  5. Bruijnzeel AW, Markou A (2003) Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats. Synapse 50:20–28PubMedCrossRefGoogle Scholar
  6. Bruijnzeel AW, Markou A (2004) Adaptations in cholinergic transmission in the ventral tegmental area associated with the affective signs of nicotine withdrawal in rats. Neuropharmacology 47:572–579PubMedCrossRefGoogle Scholar
  7. Carboni E, Tanda GL, Frau R, Di Chiara G (1990) Blockade of the noradrenaline carrier increases extracellular dopamine in the prefrontal cortex: evidence that dopamine is taken up by noradrenergic terminals. J Neurochem 55:1067–1070PubMedCrossRefGoogle Scholar
  8. Chen F, Lawrence AJ (2003) The effects of antidepressant treatment on serotonergic and dopaminergic systems in fawn-hooded rats: a quantitative autoradiography study. Brain Res 976:22–29PubMedCrossRefGoogle Scholar
  9. Covey LS, Glassman AH (1991) A meta-analysis of double-blind placebo-controlled trials of clonidine for smoking cessation. Br J Addict 86:991–998PubMedCrossRefGoogle Scholar
  10. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A (2003a) Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology 168:347–358PubMedCrossRefGoogle Scholar
  11. Cryan JF, Markou A, Lucki I (2003b) Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23(5):238–245CrossRefGoogle Scholar
  12. Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S et al (2004) Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotine receptors. Mol Pharmacol 66:675–682PubMedCrossRefGoogle Scholar
  13. Dani JA, De Biasi M (2001) Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 70:439–446PubMedCrossRefGoogle Scholar
  14. David V, Besson M, Changeux JP, Granon S, Cazala P (2006) Reinforcing effects of nicotine microinjections into the ventral tegmental area of mice: dependence on cholinergic nicotinic and dopaminergic D1 receptors. Neuropharmacology 50:1030–1040PubMedCrossRefGoogle Scholar
  15. Dews PB (1955) Studies on behavior: I. Differential sensitivity to pentobarbital of pecking performance in pigeons depending on the schedule of reward. J Pharmacol Exp Ther 138:393–401Google Scholar
  16. Dong J, Blier P (2001) Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology 155:52–57PubMedCrossRefGoogle Scholar
  17. Durcan MJ, McWilliam JR, Campbell IC, Neale MC, Dunn G (1988) Chronic antidepressant drug regimes and food and water intake in rats. Pharmacol Biochem Behav 30(2):299–302PubMedCrossRefGoogle Scholar
  18. Epping-Jordan MP, Watkins SS, Koob GF, Markou A (1998) Dramatic decreases in brain reward function during nicotine withdrawal. Nature 393:76–79PubMedCrossRefGoogle Scholar
  19. Fernstrom MH, Kupfer DJ (1988) Antidepressant-induced weight-gain: a comparison of four medications. Psychiatry Res 26(3):265–271PubMedCrossRefGoogle Scholar
  20. Ferris RM, Cooper BR, Maxwell RA (1983) Studies of bupropion’s mechanism of antidepressant activity. J Clin Psychiatry 44:74–78PubMedGoogle Scholar
  21. Fibiger HC, Phillips AG (1981) Increased intracranial self-stimulation in rats after long-term administration of desipramine. Science 214(45121):683–685PubMedCrossRefGoogle Scholar
  22. Frazer A (2001) Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. J Clin Psychiatry 12(62 Suppl):16–23Google Scholar
  23. Fryer JD, Lukas RJ (1999) Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288:88–92PubMedGoogle Scholar
  24. Geyer MA, Markou A (1995) Animal models of psychiatric disorders. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York, NY, pp 787–798Google Scholar
  25. Glick SD, Maisonneuve IM, Kitchen BA (2002) Modulation of nicotine self-administration in rats by combination therapy with agents blocking α3β4 nicotinic receptors. Eur J Pharmacol 448:185–191PubMedCrossRefGoogle Scholar
  26. Gobbi G, Slater S, Boucher N, Debonnel G, Blier P (2003) Neurochemical and psychotropic effects of bupropion in healthy male subjects. J Clin Psychopharmacol 23:233–239PubMedCrossRefGoogle Scholar
  27. Hall FS, Stellar JR, Kelley AE (1990) Acute and chronic desipramine treatment effects on rewarding electrical stimulation of the lateral hypothalamus. Pharmacol Biochem Behav 37:277–281PubMedCrossRefGoogle Scholar
  28. Harrison AA, Liem YTB, Markou A (2001) Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. Neuropsychopharmacology 25:55–71PubMedCrossRefGoogle Scholar
  29. Hennings EC, Kiss JP, Vizi ES (1997) Nicotinic acetylcholine receptor antagonist effect of fluoxetine in rat hippocampal slices. Brain Res 759:292–294PubMedCrossRefGoogle Scholar
  30. Hoffman AF, Gerhardt GA (1998) In vivo electrochemical studies of dopamine clearance in the rat substantia nigra: effects of locally applied uptake inhibitors and unilateral 6-hydroxydopamine lesions. J Neurochem 70:179–189PubMedCrossRefGoogle Scholar
  31. Hughes JR, Gust SW, Skoog K, Keenan RM, Fenwick JW (1991) Symptoms of tobacco withdrawal: a replication and extension. Arch Gen Psychiatry 48:52–59PubMedGoogle Scholar
  32. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC et al (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195–1202PubMedCrossRefGoogle Scholar
  33. Izaguirre V, Fernandez-Fernandez JM, Cena V, Gonzalez-Garcia C (1997) Tricyclic antidepressants block cholinergic nicotinic receptors and ATP secretion in bovine chromaffin cells. FEBS Lett 418:39–42PubMedCrossRefGoogle Scholar
  34. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR et al (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685–691PubMedCrossRefGoogle Scholar
  35. Kenny PJ, Markou A (2005) Conditioned nicotine withdrawal profoundly decreases the activity of brain reward systems. J Neurosci 25:6208–6212PubMedCrossRefGoogle Scholar
  36. Kokkinidis L, Zacharko RM, Predy PA (1980) Post-amphetamine depression of self-stimulation responding from the substantia nigra: reversal by tricyclic antidepressants. Pharmacol Biochem Behav 13:379–383PubMedCrossRefGoogle Scholar
  37. Koob GF, Stinus L, Le Moal M, Bloom FE (1989) Opponent process theory of motivation: neurobiological evidence from studies of opiate dependence. Neurosci Biobehav Rev 13:135–140PubMedCrossRefGoogle Scholar
  38. Kornetsky C, Esposito RU (1979) Euphorigenic drugs: effects on the reward pathways of the brain. Fed Proc 38:2473–2476PubMedGoogle Scholar
  39. Lahmame A, Armario A (1996) Differential responsiveness of inbred strains of rats to antidepressants in the forced swimming test: are Wistar Kyoto rats an animal model of subsensitivity to antidepressants? Psychopharmacology 123(2):191–198PubMedCrossRefGoogle Scholar
  40. Learned-Coughlin SM, Bergstrom M, Savitcheva I, Ascher J, Schmith VD, Langstrom B (2003) In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 54:800–805PubMedCrossRefGoogle Scholar
  41. Lerman C, LeSage MG, Perkins KA, O’Malley SS, Siegel SJ, Benowitz NL, Corrigall WA (2007) Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 6(9):746–762PubMedCrossRefGoogle Scholar
  42. Lucki I, Frazer A (1985) Performance and extinction of lever press behavior following chronic administration of desipramine to rats. Psychopharmacol 85(3):253–259CrossRefGoogle Scholar
  43. Malin DH, Lake JR, Newlin-Maultsby P, Roberts LK, Lanier JG, Carter VA et al (1992) Rodent model of nicotine abstinence syndrome. Pharmacol Biochem Behav 43:779–784PubMedCrossRefGoogle Scholar
  44. Markou A, Koob GF (1992) Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol Behav 51:111–119PubMedCrossRefGoogle Scholar
  45. Markou A, Hauger RL, Koob GF (1992) Desmethylimipramine attenuates cocaine withdrawal in rats. Psychopharmacology 109:305–314PubMedCrossRefGoogle Scholar
  46. Markou A, Weiss F, Gold LH, Caine SB, Schulteis G, Koob GF (1993) Animal models of drug craving. Psychopharmacology 112:163–182PubMedCrossRefGoogle Scholar
  47. Markou A, Kosten TR, Koob GF (1998) Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 18:135–174PubMedCrossRefGoogle Scholar
  48. Mateo Y, Fernandez-Pastor B, Meana JJ (2001) Acute and chronic effects of desipramine and clorgyline on α2-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study. Br J Pharmacol 133:1362–1370PubMedCrossRefGoogle Scholar
  49. Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S (2002) Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology 163:102–105PubMedCrossRefGoogle Scholar
  50. Miller DK, Wong EHF, Chesnut MD, Dwoskin LP (2002) Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. J Pharmacol Exp Ther 302:687–695PubMedCrossRefGoogle Scholar
  51. Mjellem N, Lund A, Hole K (1993) Reduction of NMDA-induced behaviour after acute and chronic administration of desipramine in mice. Neuropharmacology 32:591–595PubMedCrossRefGoogle Scholar
  52. National Institutes of Health (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington, DCGoogle Scholar
  53. Neumeister A, Young T, Stastny J (2004) Implications of genetic research on the role of the serotonin in depression: emphasis on the serotonin type 1A receptor and the serotonin transporter. Psychopharmacology (Berl) 174(4):512–524CrossRefGoogle Scholar
  54. Nurse B, Russell VA, Taljaard JJ (1985) Effect of chronic desipramine treatment on adrenoceptor modulation of [3H]dopamine release from rat nucleus accumbens slices. Brain Res 334:235–242PubMedCrossRefGoogle Scholar
  55. Orzack MH, Cole JO, Friedman L, Bird M, MeEachen J (1986) Weight changes in antidepressants: a comparison of amitriptyline and trazodone. Neuropsychobiology 15(S1):28–30CrossRefGoogle Scholar
  56. Paterson NE, Markou A (2007) Design of animal models and treatments for addiction and depression co-morbidity. Neurotox Res 11(1):1–32PubMedGoogle Scholar
  57. Paterson NE, Semenova S, Gasparini F, Markou A (2003) The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology 167:257–264PubMedGoogle Scholar
  58. Paterson NE, Froestl W, Markou A (2004) The GABAB receptor agonists baclofen and CGP44532 decrease nicotine self-administration in the rat. Psychopharmacology 172:179–186PubMedCrossRefGoogle Scholar
  59. Paterson NE, Balfour DJ, Markou A (2007) Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. Eur J Neurosci 25:3099–3108PubMedCrossRefGoogle Scholar
  60. Pellegrino LJ, Pellegrino AS, Cushman AJ (1979) A stereotaxic atlas of the rat brain. 2nd edn. Plenum Press, New YorkGoogle Scholar
  61. Petrie EC, Veith RC, Szot P (1998) Bupropion and desipramine increase dopamine transporter mRNA expression in the ventral tegmental area/substantia nigra of rat brain. Prog Neuropsychopharmacol Biol Psychiatry 22:845–856PubMedCrossRefGoogle Scholar
  62. Phillips G, Willner P, Sampson D, Nunn J, Muscat R (1991) Time-, schedule-, and reinforcer-dependent effects of pimozide and amphetamine. Psychopharmacology 104:125–131PubMedCrossRefGoogle Scholar
  63. Piasecki TM, Jorenby DE, Smith SS, Fiore MC, Baker TB (2003) Smoking withdrawal dynamics: II. Improved tests of withdrawal-relapse relations. J Abnorm Psychol 112:14–27PubMedCrossRefGoogle Scholar
  64. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM et al (1998) Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 391:173–177PubMedCrossRefGoogle Scholar
  65. Prochazka AV, Petty TL, Nett L, Silvers GW, Sachs DP, Rennard SI et al (1992) Transdermal clonidine reduced some withdrawal symptoms but did not increase smoking cessation. Arch Intern Med 152:2065–2069PubMedCrossRefGoogle Scholar
  66. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D (1998) A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 158:2035–2039PubMedCrossRefGoogle Scholar
  67. Proctor RN (2004) The global smoking epidemic: a history and status report. Clin Lung Cancer 5:371–376PubMedGoogle Scholar
  68. Quattrocki E, Baird A, Yurgulen-Todd D (2000) Biological aspects of the link between smoking and depression. Harv Rev Psychiatry 8:99–110PubMedCrossRefGoogle Scholar
  69. Rana B, McMorn SO, Reeve HL, Wyatt CN, Vaughan PF, Peers C (1993) Inhibition of neuronal nicotinic acetylcholine receptors by imipramine and desipramine. Eur J Pharmacol 250:247–251PubMedCrossRefGoogle Scholar
  70. Rauhut AS, Mullins SN, Dwoskin LP, Bardo MT (2002) Reboxetine: attenuation of nicotine self-administration in rats. J Pharmacol Exp Ther 303:664–672PubMedCrossRefGoogle Scholar
  71. Ressler JB, Nemeroff CB (2000) Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12(Suppl. 1):2–19PubMedCrossRefGoogle Scholar
  72. Richelson E, Pfenning M (1984) Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine release. Eur J Pharmacol 104:277–286PubMedCrossRefGoogle Scholar
  73. Ridley RM, Baker HF, Oven F, Cross AJ, Crow TJ (1982) Behavioral and biochemical effects of chronic amphetamine treatment in the vervet monkey. Psychopharmacol 78:245–251CrossRefGoogle Scholar
  74. Sanchez C, Hyttel J (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19(4):467–489PubMedCrossRefGoogle Scholar
  75. Sernagor E, Kuhn D, Vylicky L Jr, Mayer ML (1989) Open channel block of NMDA receptor responses evoked by tricyclics antidepressants. Neuron 2:1221–1227PubMedCrossRefGoogle Scholar
  76. Slemmer JE, Martin BR, Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321–327PubMedGoogle Scholar
  77. Solomon RL, Corbit JD (1973) An opponent-process theory of motivation: II. Cigarette addiction. J Abnorm Psychol 81:158–171PubMedCrossRefGoogle Scholar
  78. Stolerman IP, Jarvis MJ (1995) The scientific case that nicotine is addictive. Psychopharmacol 117:2–10CrossRefGoogle Scholar
  79. Stolerman IP, Shoaib M (1991) The neurobiology of tobacco addiction. Trends Pharmacol Sci 12:467–473PubMedCrossRefGoogle Scholar
  80. Tremblay LK, Naranjo CA, Graham SJ, Hermann N, Mayberg HS, Hevenor S, Busto UE (2005) Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch Gen Psychiatry 62(11):1228–1236PubMedCrossRefGoogle Scholar
  81. Valentino DA, Riccitelli AJ, Dufresne RL (1987) Chronic DMI reduces thresholds for brain stimulation reward in the rat. Pharmacol Biochem Behav 39:1–4CrossRefGoogle Scholar
  82. Wagena EJ, Knipschild P, Zeegers MP (2005) Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis. Addiction 100:317–326PubMedCrossRefGoogle Scholar
  83. Watkins SS, Stinus L, Koob GF, Markou A (2000) Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J Pharmacol Exp Ther 292:1053–1064Google Scholar
  84. West RJ, Hajek P, Belcher M (1989) Severity of withdrawal symptoms as a predictor of an attempt to quit smoking. Psychol Med 19:981–985PubMedCrossRefGoogle Scholar
  85. Winer BJ (1971) Statistical principles in experimental design, 2nd edn. McGraw-Hill, New York, NYGoogle Scholar
  86. Wing VC, Shoaib M (2007) Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal. Psychopharmacology (Berl) 195(3):303–313CrossRefGoogle Scholar
  87. Yamamoto BK, Novotney S (1998) Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem 71(1):274–280PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Neil E. Paterson
    • 2
  • Svetlana Semenova
    • 1
  • Athina Markou
    • 1
  1. 1.Department of Psychiatry, 0603 School of MedicineUniversity of California at San DiegoLa JollaUSA
  2. 2.Department of Psychiatry, Semel Institute for Neuroscience & Human BehaviorUniversity of California at Los AngelesLos AngelesUSA

Personalised recommendations